期刊文献+

卡培他滨单药连用3周方案治疗老年晚期消化道肿瘤疗效评价 被引量:5

Study the Capecitabine 3 Weeks a Laparoscope, Usually Connected to a Single drug for Treatment of Elderly advanced Digestive tract Tumor
下载PDF
导出
摘要 目的:研究卡培他滨单药连用3周治疗老年晚期消化道肿瘤的临床效果。方法:选取我院2012年10月~2013年10月收治的老年晚期消化道肿瘤患者64例,经患者及家属同意,分成对照组和常规组,每组各32例。对照组采用卡培他滨2000 mg/m2/d,2次服用,连用3周(21天),4周重复的用药方法;常规组采用卡培他滨2500mg/m2/d,2次服用,连用2周(14天),3周重复的用药方法。用药2个周期后评价临床疗效、不良反应。结果:对照组的有效率为34.4%(11/32),临床获益率为75.0%(24/32);常规组的有效率为31.2%(10/32),临床获益率为71.9%(23/32),2组比较,P>0.05,差异无统计学意义。对照组不良反应(恶心呕吐,手足综合征,口腔炎,腹泻)的发生率明显低于常规组,且多为Ⅰ~Ⅱ度。常规组不良反应发生率高,而且多数是Ⅲ~Ⅳ度。结论:卡培他滨单药减量并延长用药时间为3周的方案治疗老年晚期消化道肿瘤疗效好,并且不良反应较少,值得临床应用。 Objective:To study the capecitabine 3 weeks a laparoscope , usually connected to a single drug for treatment of elderly ad-vanced digestive tract tumor .Methods:From October 2012 to October 2012 treated 64 cases of elderly patients with late digestive tract tumor, with the consent of the patient and family , were divided into control group and normal group , 32 cases in each group.Result s:the effective rate was 34.4%(11/32) in the control group, the clinical benefit rate was 75.0%(24/32);Normal group, the effective rate was 31.2%(10/32), the clinical benefit rate was 71.9 %(23/32), compared two groups, P 〉0.05, there was no statistically signifi-cant difference .Conclusion:Capecitabine single reduction and prolong the use time of 3 weeks of good curative effect on senile late diges-tive tract tumor , and less adverse reactions , worthy of clinical application.
出处 《中国伤残医学》 2014年第15期15-16,共2页 Chinese Journal of Trauma and Disability Medicine
关键词 卡培他滨 老年人 消化道肿瘤 临床疗效 Capecitabine The elderly The digestive tract tumor
  • 相关文献

参考文献3

  • 1孙燕,等.抗肿瘤药物的分类和药理学基础.临床肿瘤内科手册[M].5版.北京:人民卫生出版社,2008.62.
  • 2张东伟,周晋华,吴飞雪.卡培他滨单药治疗老年晚期胃癌临床研究[J].肿瘤基础与临床,2008,21(3):238-239. 被引量:10
  • 3石国强,胡玉强.老年晚期消化道肿瘤的治疗方法[J].中国肿瘤临床与康复,2010,10(2):455-456.

二级参考文献5

  • 1王晓稼,陈占红,叶魏武,楼彩金.卡培他滨治疗消化道恶性肿瘤的药物经济学评价[J].中国处方药,2006(4):38-41. 被引量:8
  • 2Miwa M,Ura M,Nishida M,et al.Design of a novel oral fluoropyrimidine carbamate,capecitabine,which generates 5-fluuruuracil selcctively in tumors by enzymes concentrated in human liver and cancer tissue[J].Eur J Cancer,1998,34(8):1274-1281.
  • 3Schuller J,Cassidy J,Dumont E,et al.Preferential activation of capecitabine in tumor folluwing oral administration to colorectal patients[J].Cancer Chemother Pharmacol,2000,45(4):291-297.
  • 4Walko CM,Lindley C.Capecitabine:a review[J].Clin Ther,2005,27(1):23-44.
  • 5Marse H,Van Cutsem E,Grothey A,et al.Management of adverse events and other practical considerations in patients receiving capecitabine(Xeloda)[J].Eur J Oncol Nurs,2004,8 Suppl 1:S16-30.

共引文献9

同被引文献22

引证文献5

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部